JP5837481B2 - 糸球体腎炎治療 - Google Patents
糸球体腎炎治療 Download PDFInfo
- Publication number
- JP5837481B2 JP5837481B2 JP2012513512A JP2012513512A JP5837481B2 JP 5837481 B2 JP5837481 B2 JP 5837481B2 JP 2012513512 A JP2012513512 A JP 2012513512A JP 2012513512 A JP2012513512 A JP 2012513512A JP 5837481 B2 JP5837481 B2 JP 5837481B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- composition according
- compound
- glomerulonephritis
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/227—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Description
R−L−CO−X (I)
(式中、Rは、場合によってはS、O、N、SO、SO2から選ばれる1個以上のヘテロ原子またはヘテロ原子の群によって割り込まれていてもよいC10-24不飽和炭化水素基であり、当該炭化水素基は、少なくとも4個の非共役二重結合を含み;
Lは、R基と前記カルボニルCOとの間に原子を1〜5個有する橋状結合を形成する連結基であり;
Xは、電子求引基である)またはその塩である。
本発明は、糸球体腎炎および関連する症状の治療における式(I)の化合物またはその塩の使用を伴う。糸球体腎炎は、糸球体の炎症を特徴とする腎臓病である。
式中、RおよびXは、上に定義のとおりであり;
Y1は、O、S、NH、N(C1-6−アルキル)、SO、またはSO2から選ばれ、Y2は、(CH2)nまたはCH(C1-6アルキル)であるか;あるいは、
Y1およびY2は、一緒になって5員または6員の単素または複素の、場合によって不飽和または芳香性であってもよい、環を形成するか;あるいは、
Y1は、5員または6員の単素または複素の、場合によって不飽和または芳香性であってもよい、環を形成し、Y2は(CH2)nであり;
ここでnは、1〜3、好ましくは1である。
式中、RおよびXは、上に定義のとおりであり;
Y1およびY2は、一緒になって5員または6員の単素または複素の、場合によって不飽和または芳香性であってもよい、環を形成するか;あるいは、
Y1は、5員または6員の単素または複素の、場合によって不飽和または芳香性であってもよい、環を形成し、Y2は(CH2)nであり;
ここでnは、1〜3、好ましくは1である。
式中、R、n、およびXは、上に定義のとおりである。当該化合物は、特に次の化合物である。
式中、RおよびXは、上に定義のとおりであり、L’は、R基とカルボニルCOとの間に原子を1〜5個有する橋状結合を形成する連結基を表し、ここで当該L’は、環構造を含む。
式中、RおよびXは上に定義のとおりであり、Zは、例えば、ハロゲン化物などの対イオンである。当該化合物は、例えば、下記の化合物である。
(II)場合によってはN原子をメチル化すること;
(III)TFPOと反応させること;および
(IV)形成された水酸基をケトンまで酸化すること。
(ii).疾患を阻害すること、つまり、疾患の発症、またはその再発、またはその臨床的もしくは亜臨床的な症状の少なくとも1つを停止させる、減少させる、または遅延させること;あるいは
(iii).疾患の臨床的もしくは亜臨床的な症状の1つ以上を軽減させるかまたは減退させること。
図1は、メサンギウム細胞におけるサイトカイン刺激性PGE2形成に対する実施例の阻害剤の効果を示す。休止細胞を、表示の濃度のAKH−217およびAVX002の非存在下(−)または存在下で、DMEM(−)またはIL−1β(1nM)のいずれかで刺激した。上清を採取し、ELISAを用いたPGE2の定量に利用した。データは、最大のIL−1β刺激性PGE2に対する%として表し、平均±S.D.(n=3)である。
次の化合物を実験で使用した。
これらの化合物は、Chem.Soc.,Perkin Trans 1、2000、2271〜2276に基づいて合成した。
メサンギウム細胞におけるPGE2形成に対する阻害剤の効果を調査した。PGE2形成は、炎症誘発性サイトカインIL−1βによる細胞の刺激により高度に誘導される。このPGE2の誘導は、阻害剤の存在下で用量依存的に減少する。最も大きな効果は、3〜10μMのAKH−217(AVX001)および化合物B(AVX002)で見られた(図1)。
酸化窒素(NO)もまた、メサンギウム細胞のサイトカイン治療にて誘導型NO合成酵素(iNOS)により生じる炎症誘発性のメディエーターと考えられる。過去の様々な研究では、iNOS発現がsPLA2と同じ転写因子により調節されることが示されている。我々はまた、サイトカイン誘発性iNOS発現も阻害剤により影響されるかどうかを調査した。
糸球体腎炎は、第一段階では糸球体間質のアポトーシスの増加を特徴とし、第二段階では反対の事象、つまりメサンギウム細胞の過剰増殖と置き換わる。過去の様々な研究では、PDGF、インスリン、インスリン様成長因子(IGF)を含む様々な増殖因子あるいはATPおよびUTPなどの細胞外ヌクレオチドに曝露されると、培養下の静止メサンギウム細胞は、細胞周期に再び入り得ることが示されている。これらのデータはここでは、インスリン、IGF、およびATPが、DNAへの[3H]チミジン取り込みの増加を引き起こすことにより確認された(図5Aおよび図5B)。AKH217またはAVX002のいずれかの存在下では、アゴニスト刺激性[3H]チミジン取り込みは減少する(図5Aおよび図5B)。細胞をPDGFで刺激すると、同様のデータも得られた。これらのデータは、阻害剤の抗増殖能を示唆している。
Claims (11)
- 糸球体腎炎、ループス腎炎、または糖尿病性腎症の治療において用いられるための、式(I)の化合物またはその塩を含む組成物。
R−L−CO−X (I)
(式中、Rは、C10-24不飽和炭化水素基であり、当該炭化水素基は、少なくとも4個の非共役二重結合を含み;
Lは、R基と前記カルボニルCOとの間に原子を1〜5個有する橋状結合を形成する連結基であり、前記Lは、少なくとも一つのヘテロ原子を含み、前記Lは、−CH2−、−CH(C1-6アルキル)−、−N(C1-6アルキル)−、−NH−、−S−、−O−、−CH=CH−、−CO−、−SO−、または−SO2−からなる1つ以上の基から形成され;
Xは、CHal3であり、ここで、Halはハロゲンを意味する。) - 前記炭化水素基が、二重結合を5〜7個有する、請求項1に記載の組成物。
- 二重結合が前記カルボニル基と共役していない、請求項1または2に記載の組成物。
- 二重結合がいずれもシス配置である、請求項1〜3のいずれか一項に記載の組成物。
- 前記カルボニル基に最も近い二重結合を除く、すべての二重結合がシス配置である、請求項1〜3のいずれか一項に記載の組成物。
- R基が炭素原子を17〜19個含む、請求項1〜5のいずれか一項に記載の組成物。
- Lが、少なくとも1つのO、S、N、またはSOを含む、請求項1〜6のいずれかに記載の組成物。
- Lが、−SCH 2 −、−SOCH2−、または−COCH2−である、請求項1〜7のいずれかに記載の組成物。
- 前記化合物が、式(I’)
R−Y1−Y2−CO−X (I’)
(式中、RおよびXは、上に定義のとおりであり;
Y1は、O、S、NH、N(C1-6−アルキル)、SO、またはSO2から選ばれ、Y2は、(CH2)nまたはCH(C1-6アルキル)であり;
ここでnは、1〜3である)
を有する、請求項1〜7のいずれかに記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0909643.9 | 2009-06-04 | ||
GB0909643A GB0909643D0 (en) | 2009-06-04 | 2009-06-04 | Glomerulonephritis treatment |
PCT/EP2010/003384 WO2010139482A1 (en) | 2009-06-04 | 2010-06-04 | Glomerulonephritis treatment |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012528813A JP2012528813A (ja) | 2012-11-15 |
JP2012528813A5 JP2012528813A5 (ja) | 2014-05-08 |
JP5837481B2 true JP5837481B2 (ja) | 2015-12-24 |
Family
ID=40936918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012513512A Active JP5837481B2 (ja) | 2009-06-04 | 2010-06-04 | 糸球体腎炎治療 |
Country Status (14)
Country | Link |
---|---|
US (3) | US8796251B2 (ja) |
EP (2) | EP2437739B1 (ja) |
JP (1) | JP5837481B2 (ja) |
AU (1) | AU2010256013B2 (ja) |
CA (1) | CA2764465C (ja) |
CY (1) | CY1118269T1 (ja) |
DK (2) | DK2745837T3 (ja) |
ES (2) | ES2546198T3 (ja) |
GB (1) | GB0909643D0 (ja) |
HU (2) | HUE030085T2 (ja) |
LT (1) | LT2745837T (ja) |
PL (2) | PL2437739T3 (ja) |
PT (2) | PT2437739E (ja) |
WO (1) | WO2010139482A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
GB201205394D0 (en) | 2012-03-27 | 2012-05-09 | Adlens Ltd | Improvements in or relating to deformable non-round membrane assemblies |
GB201221329D0 (en) | 2012-11-27 | 2013-01-09 | Avexxin As | Dermatitis treatment |
GB201313238D0 (en) | 2013-07-24 | 2013-09-04 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
GB201409363D0 (en) | 2014-05-27 | 2014-07-09 | Avexxin As | Skin cancer treatment |
GB201501144D0 (en) | 2015-01-23 | 2015-03-11 | Avexxin As | Process for the preparation of a polyunsaturated ketone compound |
GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
KR20190055153A (ko) | 2016-09-21 | 2019-05-22 | 아벡신 에이에스 | 약학 조성물 |
EP3638221B1 (en) * | 2017-06-16 | 2021-09-29 | Avexxin AS | Compositions and methods for treatment of a fibrotic disease |
GB201910644D0 (en) | 2019-07-25 | 2019-09-11 | Coegin Pharma As | Cancer Treatment |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670465A (en) | 1986-05-21 | 1987-06-02 | Syntex (U.S.A.) Inc. | Arachidonic acid analogs |
JPH0987176A (ja) * | 1995-09-26 | 1997-03-31 | Shiseido Co Ltd | 糸球体腎炎抑制剤 |
JPH09268153A (ja) | 1996-04-02 | 1997-10-14 | Sagami Chem Res Center | トリフルオロメチルケトン誘導体及びホスホリパーゼa2阻害剤 |
EP0904072A4 (en) * | 1996-04-12 | 2003-07-30 | Peptide Technology Pty Ltd | METHODS FOR TREATING IMMUNOPATHOLOGIES USING POLYUNSATURATED FATTY ACIDS |
US6107334A (en) | 1998-02-23 | 2000-08-22 | Wake Forest University | Dietary control of arachidonic acid metabolism |
WO2000002561A1 (en) | 1998-07-13 | 2000-01-20 | University Of South Florida | Modulation of the phospholipase a2 pathway as a therapeutic |
US6031014A (en) * | 1998-12-08 | 2000-02-29 | Crivello; James V. | Initiator compositions and methods for their synthesis and use |
US20020165119A1 (en) * | 2001-01-31 | 2002-11-07 | Alan Leff | Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2 |
GB0202002D0 (en) | 2002-01-29 | 2002-03-13 | Leiv Eiriksson Nyotek A S | Use |
MY131170A (en) * | 2002-03-28 | 2007-07-31 | Nissan Chemical Ind Ltd | Therapeutic agent for glomerular disease |
CN100415224C (zh) * | 2003-03-18 | 2008-09-03 | 诺瓦提斯公司 | 包含脂肪酸和氨基酸的组合物 |
NZ552238A (en) | 2006-12-20 | 2009-07-31 | Seperex Nutritionals Ltd | An extract |
WO2008075366A2 (en) * | 2006-12-20 | 2008-06-26 | Medwell Laboratories Ltd. | Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof |
US8741966B2 (en) * | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
-
2009
- 2009-06-04 GB GB0909643A patent/GB0909643D0/en not_active Ceased
-
2010
- 2010-06-04 US US12/794,367 patent/US8796251B2/en active Active
- 2010-06-04 CA CA2764465A patent/CA2764465C/en active Active
- 2010-06-04 HU HUE14158421A patent/HUE030085T2/en unknown
- 2010-06-04 US US13/375,618 patent/US20120136066A1/en not_active Abandoned
- 2010-06-04 ES ES10722643.3T patent/ES2546198T3/es active Active
- 2010-06-04 HU HUE10722643A patent/HUE027050T2/en unknown
- 2010-06-04 JP JP2012513512A patent/JP5837481B2/ja active Active
- 2010-06-04 PT PT107226433T patent/PT2437739E/pt unknown
- 2010-06-04 EP EP10722643.3A patent/EP2437739B1/en active Active
- 2010-06-04 EP EP14158421.9A patent/EP2745837B1/en active Active
- 2010-06-04 PT PT141584219T patent/PT2745837T/pt unknown
- 2010-06-04 AU AU2010256013A patent/AU2010256013B2/en not_active Ceased
- 2010-06-04 DK DK14158421.9T patent/DK2745837T3/en active
- 2010-06-04 ES ES14158421.9T patent/ES2587719T3/es active Active
- 2010-06-04 PL PL10722643T patent/PL2437739T3/pl unknown
- 2010-06-04 WO PCT/EP2010/003384 patent/WO2010139482A1/en active Application Filing
- 2010-06-04 DK DK10722643.3T patent/DK2437739T3/en active
- 2010-06-04 LT LTEP14158421.9T patent/LT2745837T/lt unknown
- 2010-06-04 PL PL14158421T patent/PL2745837T3/pl unknown
-
2014
- 2014-03-07 US US14/200,238 patent/US9187396B2/en not_active Expired - Fee Related
-
2016
- 2016-08-24 CY CY20161100833T patent/CY1118269T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT2437739E (pt) | 2015-10-12 |
US20100311843A1 (en) | 2010-12-09 |
EP2437739A1 (en) | 2012-04-11 |
WO2010139482A1 (en) | 2010-12-09 |
US8796251B2 (en) | 2014-08-05 |
US9187396B2 (en) | 2015-11-17 |
US20120136066A1 (en) | 2012-05-31 |
LT2745837T (lt) | 2016-10-25 |
PL2437739T3 (pl) | 2015-11-30 |
EP2437739B1 (en) | 2015-07-29 |
AU2010256013B2 (en) | 2013-05-16 |
EP2745837B1 (en) | 2016-07-27 |
CA2764465A1 (en) | 2010-12-09 |
DK2437739T3 (en) | 2015-08-17 |
DK2745837T3 (en) | 2016-08-29 |
AU2010256013A1 (en) | 2012-01-12 |
EP2745837A1 (en) | 2014-06-25 |
HUE027050T2 (en) | 2016-08-29 |
PL2745837T3 (pl) | 2017-01-31 |
ES2587719T3 (es) | 2016-10-26 |
US20140256824A1 (en) | 2014-09-11 |
CA2764465C (en) | 2018-03-20 |
CY1118269T1 (el) | 2017-06-28 |
ES2546198T3 (es) | 2015-09-21 |
GB0909643D0 (en) | 2009-07-22 |
PT2745837T (pt) | 2016-08-22 |
JP2012528813A (ja) | 2012-11-15 |
HUE030085T2 (en) | 2017-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5837481B2 (ja) | 糸球体腎炎治療 | |
AU2011298340B2 (en) | Rheumatoid arthritis treatment using polyunsaturated long chain ketones | |
JP6266642B2 (ja) | 皮膚炎治療 | |
JP6689078B2 (ja) | 超高純度なテトラヒドロカンナビノール−11−酸 | |
JP2010530901A5 (ja) | ||
JP7184241B2 (ja) | ベンズヒドリルチオアセトアミド化合物を有効成分として含む線維化疾患の治療用組成物 | |
JPWO2009096455A1 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
US20130023504A1 (en) | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | |
IL291898A (en) | Quinone-, hydroquinone-, and naphthoquinone- analogs of vetiquinone for the treatment of mitochondrial disorders | |
JP6598224B2 (ja) | ヒドロキサメートトリテルペノイド誘導体 | |
CN112672742B (zh) | 纤维化治疗用医药组合物 | |
JP2013043851A (ja) | 抗酸化ストレス酵素発現誘導剤 | |
JP7417322B2 (ja) | 神経変性疾患及び/又はその臨床的状態を抑制及び/又は治療するための組成物及び方法 | |
JP4481660B2 (ja) | エストロン誘導体およびその製造方法 | |
TW201943716A (zh) | 吳茱萸次鹼類似物及其應用 | |
JP2017081866A (ja) | 線維症の治療剤又は予防剤 | |
WO2014162106A1 (fr) | Nouveaux derives de chalcone presentant une activite anti-allergique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130520 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140703 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140929 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150729 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150918 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151015 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5837481 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |